ClinicalTrials.gg
CompletedNCT02859961Updated Mar 4, 2026Results posted

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

A Phase 2/3 interventional study of PRO 140 (350 mg) and PRO 140 (525 mg) in HIV, sponsored by CytoDyn, Inc.. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by CytoDyn, Inc. · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
562
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study is a Phase 2b/3, multi-center study designed to evaluate the efficacy, safety, and tolerability of the strategy of shifting clinically stable patients receiving suppressive combination antiretroviral therapy to PRO 140 monotherapy and maintaining viral suppression for 48 weeks following study entry.

Consenting patients will be shifted from combination antiretroviral regimen to weekly PRO 140 monotherapy for 48 weeks during the Treatment Phase with the one week overlap of existing retroviral regimen and PRO 140 at the beginning of the study treatment and also one week overlap at the end of the treatment in subjects who do not experience virologic failure.

Read the detailed description

The primary objective is to assess the treatment strategy of using PRO 140 SC as long-acting, single-agent maintenance therapy for the chronic suppression of CCR5-tropic HIV-1 infection. In addition, the prognostic factors of therapeutic success of PRO 140 monotherapy will be evaluated.

The secondary objective of the trial is to assess the clinical efficacy, safety and tolerability parameters following substitution of combination antiretroviral therapy with weekly PRO 140 monotherapy.

02

Conditions studied

  • HIV
03

In context

Lead sponsor

CytoDyn, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 12 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females, age ≥18 years
  2. Receiving combination antiretroviral therapy for last 24 weeks
  3. No change in ART within last 4 weeks prior to Screening Visit
  4. Subject has two or more potential alternative approved ART drug options to consider.
  5. Exclusive CCR5-tropic virus at Screening Visit
  6. Plasma -1 RNA \< 50 copies/mL at Screening Visit
  7. of > 200 cells/mm3 since initiation of anti-retroviral therapy
  8. CD4 cell count of > 350 cells/mm3 in preceding 24 weeks and at Screening Visit
  9. Laboratory values at Screening of:

    1. (ANC) ≥ 750/mm3
    2. (Hb) ≥ 10.5 gm/dL (male) or ≥ 9.5 gm/dL (female)
    3. ≥ 75,000 /mm3
    4. Serum (SGPT/ALT) \< 5 x (ULN)
    5. Serum aspartate transaminase (SGOT/AST) \< 5 x ULN
    6. (total) \< 2.5 x ULN unless Gilbert's disease is present or subject is receiving atazanavir in the absence of other evidence of significant liver disease
    7. Creatinine ≤ 1.5 x ULN
  10. Clinically normal resting 12-lead at Screening Visit or, if abnormal, considered not by the Principal Investigator.
  11. Both male and female patients and their partners of must agree to use 2 medically accepted methods of during the course of the study.
  12. Willing and able to participate in all aspects of the study, including use of SC medication, completion of subjective evaluations, attendance at scheduled clinic visits, and compliance with all protocol requirements as evidenced by providing written .

Exclusion criteria

Exclusion Criteria:

  1. CXCR4-tropic virus or dual/mixed tropic (R5X4) virus determined by the Trofile™ DNA Assay
  2. infection as manifest by the presence of Hepatitis B surface antigen (HBsAg)
  3. Any active infection or requiring acute therapy (with the exception of local cutaneous Kaposi's sarcoma)
  4. Laboratory test values ≥ grade 4 DAIDS laboratory abnormality.
  5. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study
  6. Unexplained fever or illness within 1 week prior to the first study dose
  7. Any vaccination within 2 weeks prior to the first study dose or during the study.
  8. Subjects who have failed on a maraviroc containing regimen.
  9. Subjects weighing \< 35kg
  10. History of anaphylaxis to any oral or parenteral drugs
  11. History of Bleeding Disorder or patients on anti-coagulant therapy
  12. Participation in an experimental drug trial(s) within 30 days of the Screening Visit
  13. Any known allergy or antibodies to the study drug or
  14. Treatment with any of the following:

    1. Radiation or cytotoxic chemotherapy with 30 days prior to the screening visit
    2. within 60 days prior to the screening visit
    3. Immunomodulating agents (e.g., interleukins, interferons), hydroxyurea, or foscarnet within 60 days prior to the screening visit
    4. Oral or parenteral within 30 days prior to the Screening Visit. Subjects on chronic steroid therapy > 5 mg/day will be excluded with the following exception:

      • Subjects on inhaled, nasal, or topical steroids will not be excluded
  15. Any other clinical condition that, in the Investigator's judgment, would potentially compromise study compliance or the ability to evaluate safety/efficacy
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
562 participants (actual)

Study arms

  • Experimental
    Part 1 - 350 mg weekly injections of PRO 140, no VF (Group A)

    350 mg SC injections of PRO 140 per week, patients who had no Virologic Failure (VF)

    Drug: PRO 140 (350 mg)

  • Experimental
    Part 1 - 525 mg weekly injections of PRO 140, no VF (Group B)

    525 mg SC injections of PRO 140 per week, patients who had no Virologic Failure (VF)

    Drug: PRO 140 (525 mg)

  • Experimental
    Part 1 - 700 mg weekly injections of PRO 140 (Group C)

    700 mg SC injections of PRO 140 per week

    Drug: PRO 140 (700 mg)

  • Experimental
    Part 2 - Rescue Arm for Group A, 525 mg PRO 140

    525 mg SC injections of PRO 140 per week after experiencing virologic failure on 350 mg dose

    Drug: PRO 140 (525 mg)

  • Experimental
    Part 2 - Rescue Arm for Group B, 700 mg PRO 140

    700 mg SC injections of PRO 140 per week after experiencing virologic failure on 525 mg dose

    Drug: PRO 140 (700 mg)

  • Experimental
    Part 2 - Rescue Arm for Group A, 700 mg PRO 140

    700 mg SC injections of PRO 140 per week after experiencing virologic failure on 350 mg dose

    Drug: PRO 140 (700 mg)

Interventions

  • PRO 140 350 mg (175 mg/mL) SC injection per week

    Also known as: Leronlimab

  • PRO 140 525 mg (175 mg/mL) SC injection per week

    Also known as: Leronlimab

  • PRO 140 700 mg (175 mg/mL) SC injection per week

    Also known as: Leronlimab

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure

    The proportion of participants experiencing virologic failure was analyzed and reported. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

Secondary outcomes

  1. Proportion of Participants Experiencing Virologic Failure While on PRO 140 Monotherapy Regimen

    Proportion of participants experiencing virologic failure while on PRO 140 monotherapy arm of the study.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

  2. Time to Virologic Failure After Initiating PRO 140 Monotherapy

    The average time to virologic failure after initiating PRO 140 monotherapy was measured in days for confirmed viral load. For the censored subjects (i.e. subjects who did not have an event) the date of event was the time of the last visit date. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

  3. Proportion of Participants Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure.

    Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.

    Time frame: From T1 (first treatment administration) to subsequent visit when viral re-suppression achieved (up to 52 weeks).

  4. Time to Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure

    Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.

    Time frame: From T1 (first treatment administration) to subsequent visit when viral re-suppression achieved (up to 52 weeks).

  5. Proportion of Participants With Viral Suppression (HIV-1 RNA < 50 Copies/mL) at Week 48 From the Start of PRO 140 Treatment Phase.

    Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

  6. Measurement of Treatment Adherence to the PRO 140 Monotherapy Regimen

    Treatment adherence in the Safety Population for all three treatment groups is provided. Measurement is proportion of subjects that reached treatment week 25 (T25)

    Time frame: From T1 (first treatment administration) to week 25 (T25).

  7. Total Time That Participants Remain Off Combination ART Regimen, Defined as the Time Between Start of PRO 140 Monotherapy and Restart of Combination ART Regimen

    Total time that participants remain off combination ART regimen will be calculated, defined as the time between start of PRO 140 monotherapy and restart of combination ART Regimen.

    Time frame: From T1 (first treatment administration) to last visit, up to 20 months.

  8. Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase

    Mean change in CD4 cell count from baseline to final visit for each participant within the Treatment Phase was calculated and summarized. Visit 48 values were imputed using the last observation carried forward if missing.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

  9. Proportion of Participants Within Each Treatment Group Experiencing Emerging Resistance

    Proportion of participants experiencing emerging resistance exhibited by fold increase (\>= 3-fold increase) in maraviroc and PRO 140 FC (IC90 relative to wild-type virus) between baseline and the time of virologic failure, as a measure of post-baseline phenotypic resistance.

    Time frame: From T1 (first treatment administration) to VF visit (up to 7 months).

  10. Mean HIV-1 RNA Concentrations in CSF in Central Nervous System (CNS) Sub-study

    Central Nervous System (CNS) sub-study Data: mean level of HIV-1 RNA in CSF (cerebrospinal fluid) at T1 (prior to first dose of PRO 140), T4, and VF visits for each treatment group.

    Time frame: From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).

  11. Mean PRO 140 Concentration in Plasma for Central Nervous System (CNS) Sub-study

    PRO 140 concentrations were measured in plasma for a subset of participants at T1, T4, and VF timepoints. Participants contributed data only at timepoints where valid measurements were available. Timepoints with missing or invalid data were excluded.

    Time frame: From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).

  12. Mean PRO 140 Concentrations in CSF for Central Nervous System (CNS) Sub-study

    PRO 140 concentrations were measured in CSF (cerebrospinal fluid) in a subset of participants at visits T1, T4, and VF.

    Time frame: From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).

  13. Mean HIV-1 RNA Concentrations in Genital Secretion in Genitourinary (GU) Sub-study

    Level of HIV-1 RNA in genital secretion at T1 (prior to first dose of PRO 140), T4, and T16 visits.

    Time frame: From T1 (first treatment administration), T4 visit (week 4), and T16 visit (up to 16 weeks).

Other outcomes

  1. Tolerability of Repeated Subcutaneous Administration of PRO 140

    Tolerability of repeated subcutaneous administration of PRO 140 as assessed by study participants (using Visual Analogue Scale). Subjects were asked to mark the point that best represents the average pain intensity at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks. Possible scores range from 0 to 100, with higher scores indicating greater pain.

    Time frame: From T1 (first treatment administration) to week 48 (T48)

  2. Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale

    Adverse Events (AEs) are presented based on severity, per Investigator discretion. Severity grades were based on the Division of Aids (DAIDS) grading guidelines. For safety analyses, Grade 3 and 4 AEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, AEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

  3. Frequency of Treatment-Emergent Serious Adverse Events

    Serious adverse events (SAEs) that occurred during the study include all adverse events that occurred from when the subject signed the informed consent form. For safety analyses, SAEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, SAEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.

    Time frame: From T1 (first treatment administration) to week 48 (T48).

07

Results

Posted Mar 4, 2026
Limitations and caveats
The outcome and safety data came from a report from the contract research organization that oversaw the study.

Participant flow

Study Start Date: 07 DEC 2016 (first subject enrolled)

Part 1, Main Treatment Phase
Participant flow — Part 1, Main Treatment Phase
MilestonePart 1 - 350 mg Weekly Injection, Group APart 1 - 525 mg Weekly Injection, Group BPart 1 - 700 mg Weekly Injection, Group C
Started226205131
Completed1107023
Not completed116135108
Part 2, Rescue Arm for Group A and B
Participant flow — Part 2, Rescue Arm for Group A and B
MilestonePart 1 - 350 mg Weekly Injection, Group APart 1 - 525 mg Weekly Injection, Group BPart 1 - 700 mg Weekly Injection, Group C
Started69650
Completed32300
Not completed37350

Outcome measures

PrimaryProportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure

The proportion of participants experiencing virologic failure was analyzed and reported. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Number · proportion of participants
Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure
proportion of participantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Proportion of Participants Who Remain on PRO 140 Monotherapy Regimen at the End of Week 48 Without Experiencing Virologic Failure0.230.430.45
SecondaryProportion of Participants Experiencing Virologic Failure While on PRO 140 Monotherapy Regimen

Proportion of participants experiencing virologic failure while on PRO 140 monotherapy arm of the study.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Number · proportion of participants
Proportion of Participants Experiencing Virologic Failure While on PRO 140 Monotherapy Regimen
proportion of participantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Proportion of Participants Experiencing Virologic Failure While on PRO 140 Monotherapy Regimen0.660.420.41
SecondaryTime to Virologic Failure After Initiating PRO 140 Monotherapy

The average time to virologic failure after initiating PRO 140 monotherapy was measured in days for confirmed viral load. For the censored subjects (i.e. subjects who did not have an event) the date of event was the time of the last visit date. Virological failure is defined as two consecutive plasma HIV-1 RNA levels of \>= 200 copies/mL.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Mean · Days
Time to Virologic Failure After Initiating PRO 140 Monotherapy
DaysPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Time to Virologic Failure After Initiating PRO 140 Monotherapy136.9 ± 115.5197.7 ± 132.4200.6 ± 133.5
SecondaryProportion of Participants Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure.

Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.

Time frame:
From T1 (first treatment administration) to subsequent visit when viral re-suppression achieved (up to 52 weeks).
Reported as:
Number · portion of participants
Proportion of Participants Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure.
portion of participantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Proportion of Participants Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure.0.920.79—
SecondaryTime to Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure

Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.

Time frame:
From T1 (first treatment administration) to subsequent visit when viral re-suppression achieved (up to 52 weeks).
Reported as:
Mean · Days
Time to Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure
DaysPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Time to Achieving Viral Suppression (HIV-1 RNA < 50 Copies/mL) After Experiencing Virologic Failure78.6 ± 55.1260.89 ± 60.33—
SecondaryProportion of Participants With Viral Suppression (HIV-1 RNA < 50 Copies/mL) at Week 48 From the Start of PRO 140 Treatment Phase.

Virologic suppression was defined as plasma HIV-1 RNA levels \< 50 copies/mL as quantified by Human Immunodeficiency Virus 1 (HIV-1) Quantitative, RNA (Taqman® Real-Time PCR) assay.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Number · portion of participants
Proportion of Participants With Viral Suppression (HIV-1 RNA < 50 Copies/mL) at Week 48 From the Start of PRO 140 Treatment Phase.
portion of participantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Proportion of Participants With Viral Suppression (HIV-1 RNA < 50 Copies/mL) at Week 48 From the Start of PRO 140 Treatment Phase.0.330.540.41
SecondaryMeasurement of Treatment Adherence to the PRO 140 Monotherapy Regimen

Treatment adherence in the Safety Population for all three treatment groups is provided. Measurement is proportion of subjects that reached treatment week 25 (T25)

Time frame:
From T1 (first treatment administration) to week 25 (T25).
Reported as:
Count of participants · Participants
Measurement of Treatment Adherence to the PRO 140 Monotherapy Regimen
ParticipantsPart1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Measurement of Treatment Adherence to the PRO 140 Monotherapy Regimen11111654
SecondaryTotal Time That Participants Remain Off Combination ART Regimen, Defined as the Time Between Start of PRO 140 Monotherapy and Restart of Combination ART Regimen

Total time that participants remain off combination ART regimen will be calculated, defined as the time between start of PRO 140 monotherapy and restart of combination ART Regimen.

Time frame:
From T1 (first treatment administration) to last visit, up to 20 months.
Reported as:
Mean · days
Total Time That Participants Remain Off Combination ART Regimen, Defined as the Time Between Start of PRO 140 Monotherapy and Restart of Combination ART Regimen
daysPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Total Time That Participants Remain Off Combination ART Regimen, Defined as the Time Between Start of PRO 140 Monotherapy and Restart of Combination ART Regimen201.53 ± 131.82250.48 ± 164.43273.25 ± 167.63
SecondaryMean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase

Mean change in CD4 cell count from baseline to final visit for each participant within the Treatment Phase was calculated and summarized. Visit 48 values were imputed using the last observation carried forward if missing.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Mean · cells/uL
Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase
cells/uLPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Mean Change in CD4 Cell Count, at Each Visit Within the Treatment Phase-41.1 ± 219.3-7.4 ± 217.37.6 ± 245.4
SecondaryProportion of Participants Within Each Treatment Group Experiencing Emerging Resistance

Proportion of participants experiencing emerging resistance exhibited by fold increase (\>= 3-fold increase) in maraviroc and PRO 140 FC (IC90 relative to wild-type virus) between baseline and the time of virologic failure, as a measure of post-baseline phenotypic resistance.

Time frame:
From T1 (first treatment administration) to VF visit (up to 7 months).
Reported as:
Number · proportion of participants
Proportion of Participants Within Each Treatment Group Experiencing Emerging Resistance
proportion of participantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
Proportion of Participants Within Each Treatment Group Experiencing Emerging Resistance0.230.130.13
SecondaryMean HIV-1 RNA Concentrations in CSF in Central Nervous System (CNS) Sub-study

Central Nervous System (CNS) sub-study Data: mean level of HIV-1 RNA in CSF (cerebrospinal fluid) at T1 (prior to first dose of PRO 140), T4, and VF visits for each treatment group.

Time frame:
From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).
Reported as:
Geometric mean · c/mL
Mean HIV-1 RNA Concentrations in CSF in Central Nervous System (CNS) Sub-study
c/mLPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
T1 (prior to first dose) visit—1.56 ± 5.601.51 ± 4.23
T4 visit—1.90 ± 11.931.60 ± 3.57
VF visit—1 ± 020.1 ± 17.6
SecondaryMean PRO 140 Concentration in Plasma for Central Nervous System (CNS) Sub-study

PRO 140 concentrations were measured in plasma for a subset of participants at T1, T4, and VF timepoints. Participants contributed data only at timepoints where valid measurements were available. Timepoints with missing or invalid data were excluded.

Time frame:
From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).
Reported as:
Mean · ng/mL
Mean PRO 140 Concentration in Plasma for Central Nervous System (CNS) Sub-study
ng/mLPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart1 - 700 mg Weekly Injections of PRO 140, Group C
Visit T180 ± 080 ± 080 ± 0
Visit T415861.03 ± 9605.1021126.59 ± 8953.9330672.09 ± 19165.06
Visit VF1536.50 ± 3501.5931713.25 ± 16122.0316278.38 ± 24824.48
SecondaryMean PRO 140 Concentrations in CSF for Central Nervous System (CNS) Sub-study

PRO 140 concentrations were measured in CSF (cerebrospinal fluid) in a subset of participants at visits T1, T4, and VF.

Time frame:
From T1 (first treatment administration), T4 (week 4), and VF visit (up to 7 months).
Reported as:
Geometric mean · ng/mL
Mean PRO 140 Concentrations in CSF for Central Nervous System (CNS) Sub-study
ng/mLPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group C
T1 visit25 ± 025 ± 025 ± 0
T4 visit30.87 ± 16.4440.84 ± 677.8963.78 ± 78.47
VF visit—47.91 ± 47.2394.27 ± 269.45
SecondaryMean HIV-1 RNA Concentrations in Genital Secretion in Genitourinary (GU) Sub-study

Level of HIV-1 RNA in genital secretion at T1 (prior to first dose of PRO 140), T4, and T16 visits.

Time frame:
From T1 (first treatment administration), T4 visit (week 4), and T16 visit (up to 16 weeks).
Reported as:
Geometric mean · c/mL
Mean HIV-1 RNA Concentrations in Genital Secretion in Genitourinary (GU) Sub-study
c/mLPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections for PRO 140, Group C
T1 visit—1 ± 01 ± 0
T4 visit—1 ± 01 ± 0
T16 visit258 ± 038.83 ± 1065.61—
Other pre-specifiedTolerability of Repeated Subcutaneous Administration of PRO 140

Tolerability of repeated subcutaneous administration of PRO 140 as assessed by study participants (using Visual Analogue Scale). Subjects were asked to mark the point that best represents the average pain intensity at the injection site on a horizontal line (100 mm in length) anchored by the following word descriptors at each end, "no pain" on the left side and "pain as bad as it could possibly be" on the right side of the line. The VAS score is determined by measuring in millimeters from the left-hand end of the line to the point that the patient marks. Possible scores range from 0 to 100, with higher scores indicating greater pain.

Time frame:
From T1 (first treatment administration) to week 48 (T48)
Reported as:
Mean · score on a scale
Tolerability of Repeated Subcutaneous Administration of PRO 140
score on a scalePart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections for PRO 140, Group C
Left Side0.84 ± 1.300.91 ± 2.821.08 ± 1.70
Right Side0.87 ± 1.330.90 ± 1.410.98 ± 1.94
Other pre-specifiedFrequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale

Adverse Events (AEs) are presented based on severity, per Investigator discretion. Severity grades were based on the Division of Aids (DAIDS) grading guidelines. For safety analyses, Grade 3 and 4 AEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, AEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Count of participants · Participants
Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale
ParticipantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group CPart 2 - Group APart 2 - Group B
Frequency of Grade 3 or 4 Adverse Events as Defined by the DAIDS Adverse Event Scale188843
Other pre-specifiedFrequency of Treatment-Emergent Serious Adverse Events

Serious adverse events (SAEs) that occurred during the study include all adverse events that occurred from when the subject signed the informed consent form. For safety analyses, SAEs were summarized separately for treatment periods corresponding to Part 1 and Part 2 due to differences in dosing and treatment exposure. Participants who entered Part 2 (rescue treatment) received an increased dose of leronlimab and therefore constitute a distinct safety population. For this reason, SAEs occurring during Part 2 are represented separately from Part 1, although Part 2 does not represent a separate study arm for efficacy analyses and participants remain attributed to their original Part 1 treatment arm in the overall study design.

Time frame:
From T1 (first treatment administration) to week 48 (T48).
Reported as:
Count of participants · Participants
Frequency of Treatment-Emergent Serious Adverse Events
ParticipantsPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group CPart 2 - Group APart 2 - Group B
Frequency of Treatment-Emergent Serious Adverse Events1612743

Adverse events

Collected over Adverse events were reported from the time of the first treatment visit and continued up until the final study visit, up to 22 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - 350 mg Weekly Injections of PRO 140, Group A1/226 (0.4%)16/226 (7.1%)119/226 (52.7%)
Part 1 - 525 mg Weekly Injections of PRO 140, Group B1/205 (0.5%)12/205 (5.9%)41/205 (20%)
Part 1 - 700 mg Weekly Injections of PRO 140, Group C1/131 (0.8%)7/131 (5.3%)28/131 (21.4%)
Part 2 - Group A0/69 (0%)4/69 (5.8%)30/69 (43.5%)
Part 2 - Group B0/65 (0%)3/65 (4.6%)22/65 (33.8%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group CPart 2 - Group APart 2 - Group B
DehydrationMetabolism and nutrition disorders1/2260/2050/1310/691/65
SeizuresNervous system disorders0/2260/2050/1310/691/65
BacteremiaInfections and infestations0/2260/2050/1310/691/65
PneumoniaInfections and infestations1/2261/2050/1311/691/65
Cerebrovascular accidentNervous system disorders0/2260/2052/1310/690/65
Coronary Artery DiseaseCardiac disorders0/2260/2051/1311/690/65
Localised infectionInfections and infestations0/2260/2050/1311/690/65
Meningitis asepticInfections and infestations0/2260/2050/1311/690/65
CellulitisInfections and infestations0/2261/2050/1311/690/65
GastroenteritisGastrointestinal disorders0/2262/2050/1310/690/65
Most frequent other events
Showing 10 of 16
Most frequent other events
EventPart 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140, Group CPart 2 - Group APart 2 - Group B
Upper respiratory tract infectionInfections and infestations20/22614/2059/13112/6912/65
Viral upper respiratory tract infectionInfections and infestations6/2268/2054/13110/694/65
DiarrhoeaGastrointestinal disorders20/2269/2055/1316/696/65
FatigueGeneral disorders19/2266/2055/1313/693/65
Injection site haemorrhageGeneral disorders18/2266/2051/1315/691/65
HeadacheNervous system disorders18/2269/2056/1315/695/65
NauseaGastrointestinal disorders16/2267/2052/1314/695/65
Back painMusculoskeletal and connective tissue disorders13/2262/2053/1315/692/65
NasopharyngitisInfections and infestations9/2266/2051/1315/691/65
Injection site painGeneral disorders14/2266/2051/1312/690/65

Baseline characteristics

69 participants enrolled from Part1 - Group A into Part 2 - Group A; 65 participants enrolled from Part 1 - Group B into Part 2 - Group B.

Age, Continuous
Age, Continuous(years)Part 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140 Group CTotal
Mean49.9 ± 12.448.6 ± 12.949.8 ± 11.649.4 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)Part 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140 Group CTotal
Female424438124
Male18416193438
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140 Group CTotal
American Indian or Alaska Native4206
Asian4307
Native Hawaiian or Other Pacific Islander3104
Black or African American627553190
White14911877344
More than one race2204
Unknown or Not Reported2417
Region of Enrollment
Region of Enrollment(participants)Part 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140 Group CTotal
United States226205131562
Years of HIV Diagnosis
Years of HIV Diagnosis(years)Part 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140 Group CTotal
Mean17.8 ± 9.4416.6 ± 10.316.1 ± 9.1617.1 ± 9.69
Mean Treatment Duration
Mean Treatment Duration(days)Part 1 - 350 mg Weekly Injections of PRO 140, Group APart 1 - 525 mg Weekly Injections of PRO 140, Group BPart 1 - 700 mg Weekly Injections of PRO 140 Group CTotal
Mean185.5 ± 125.8197.4 ± 111.4159.9 ± 101.36189.9 ± 116
08

Study locations

12 sites
  • CD03 Investigational site
    La Mesa, California 91942, United States
  • CD03 Investigational site
    Palm Springs, California 92262, United States
  • CD03 Investigational site
    San Francisco, California 94115, United States
  • CD03 Investigational site
    New Haven, Connecticut 06510, United States
  • CD03 Investigational site
    Norwalk, Connecticut 06850, United States
  • CD03 Investigational site
    Ft. Pierce, Florida 34982, United States
  • CD03 Investigational site
    Orlando, Florida 32803, United States
  • CD03 Investigational site
    West Palm Beach, Florida 33401, United States
  • CD03 Investigational site
    Wichita, Kansas 67214, United States
  • CD03 Investigational site
    Las Vegas, Nevada 89109, United States
  • CD03 Investigational site
    New York, New York 10011, United States
  • CD03 Investigational site
    Syracuse, New York 13210, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2016 to primary completion in Sep 2020, 45 months.

Results were first posted in Mar 2026, 5 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2016
First posted
Aug 9, 2016
StartActual
Dec 7, 2016
Primary completionActual
Sep 16, 2020
CompletionActual
Dec 7, 2020
Results first posted
Mar 4, 2026
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02859961
Lead sponsor
CytoDyn, Inc.
Responsible party
Sponsor
First posted
Aug 9, 2016
Start date
Dec 7, 2016
Primary completion
Sep 16, 2020
Completion
Dec 7, 2020
Results posted
Mar 4, 2026
Last update
Mar 4, 2026

Study contacts

Jacob Lalezari, MD
study director · CytoDyn, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion